Treat Alzheimer disease before it is symptomatic

Archives of Neurology

Volumn 68, Issue 10, 2011, Pages 1237-1238

  Rosenberg, Roger N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; DNA VACCINE;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; EDITORIAL; HUMAN; NEUROPATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; HUMANS; MALE;

EID: 80053918106     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.135     Document Type: Editorial

References (13)

1. Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline [published online June 13, 2011]. Arch Neurol. 2011;68(10): 1257-1266.
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamicbiomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9(1):119-128.
3. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216-223. (Pubitemid 351978111)
4. Rosenberg RN. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry. 2005;62(11):1186-1192. (Pubitemid 41586918)
5. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535-539. (Pubitemid 34288854)
6. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082):352-357.
7. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006;9(3)(suppl):151-153. (Pubitemid 44253307)
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353- 356. (Pubitemid 34790756)
9. De Meyer G, Shapiro F, Vanderstichele H, et al Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949-956.
10. Herskovits AZ, Growdon JH. Sharpen that needle. Arch Neurol. 2010;67(8):918- 920.
11. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wildtype mouse model. JAMA. 2009;302(16):1796-1802.
12. Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN. Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine. 2010;28(32):5280-5287.
13. Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against Amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen specific Th1 and Th17 cell proliferation [published online April 6, 2011]. Cell Mol Neurobiol. doi:10.1007/s10571-011-9680-7.